DK85193D0 - Suppression of inhibitors - Google Patents

Suppression of inhibitors

Info

Publication number
DK85193D0
DK85193D0 DK93851A DK85193A DK85193D0 DK 85193 D0 DK85193 D0 DK 85193D0 DK 93851 A DK93851 A DK 93851A DK 85193 A DK85193 A DK 85193A DK 85193 D0 DK85193 D0 DK 85193D0
Authority
DK
Denmark
Prior art keywords
ipnme
methods
compounds
malignant tumour
suppression
Prior art date
Application number
DK93851A
Other languages
English (en)
Inventor
Nils Bruenner
John Roemer
Vincent Ellis
Charles Pyke
Jan Groendahl-Hansen
Helle Pedersen
Heine Hoei Hansen
Keld Danoe
Original Assignee
Cancerforskningsfondet Af 1989
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancerforskningsfondet Af 1989 filed Critical Cancerforskningsfondet Af 1989
Priority to DK93851A priority Critical patent/DK85193D0/da
Publication of DK85193D0 publication Critical patent/DK85193D0/da
Priority to DE69433685T priority patent/DE69433685T2/de
Priority to JP7504300A priority patent/JPH10500097A/ja
Priority to AU71833/94A priority patent/AU7183394A/en
Priority to PCT/DK1994/000288 priority patent/WO1995002413A1/en
Priority to EP94920904A priority patent/EP0712312B1/en
Priority to AT94920904T priority patent/ATE263569T1/de
Priority to ES94920904T priority patent/ES2217268T3/es
Priority to US08/583,129 priority patent/US6224865B1/en
Priority to US09/836,323 priority patent/US20010034327A1/en
Priority to US10/336,513 priority patent/US20030096755A1/en
Priority to US11/964,334 priority patent/US20080166354A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK93851A 1993-07-16 1993-07-16 Suppression of inhibitors DK85193D0 (da)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DK93851A DK85193D0 (da) 1993-07-16 1993-07-16 Suppression of inhibitors
US08/583,129 US6224865B1 (en) 1993-07-16 1994-07-18 Suppression of inhibitors
PCT/DK1994/000288 WO1995002413A1 (en) 1993-07-16 1994-07-18 Suppression of inhibitors
JP7504300A JPH10500097A (ja) 1993-07-16 1994-07-18 阻害因子の抑制
AU71833/94A AU7183394A (en) 1993-07-16 1994-07-18 Suppression of inhibitors
DE69433685T DE69433685T2 (de) 1993-07-16 1994-07-18 Unterdrückung von inhibitoren
EP94920904A EP0712312B1 (en) 1993-07-16 1994-07-18 Suppression of inhibitors
AT94920904T ATE263569T1 (de) 1993-07-16 1994-07-18 Unterdrückung von inhibitoren
ES94920904T ES2217268T3 (es) 1993-07-16 1994-07-18 Supresion de inhibidores.
US09/836,323 US20010034327A1 (en) 1993-07-16 2001-04-18 Suppression of inhibitors
US10/336,513 US20030096755A1 (en) 1993-07-16 2003-01-02 Suppression of inhibitors
US11/964,334 US20080166354A1 (en) 1993-07-16 2007-12-26 Suppression of inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93851A DK85193D0 (da) 1993-07-16 1993-07-16 Suppression of inhibitors

Publications (1)

Publication Number Publication Date
DK85193D0 true DK85193D0 (da) 1993-07-16

Family

ID=8098263

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93851A DK85193D0 (da) 1993-07-16 1993-07-16 Suppression of inhibitors

Country Status (9)

Country Link
US (4) US6224865B1 (da)
EP (1) EP0712312B1 (da)
JP (1) JPH10500097A (da)
AT (1) ATE263569T1 (da)
AU (1) AU7183394A (da)
DE (1) DE69433685T2 (da)
DK (1) DK85193D0 (da)
ES (1) ES2217268T3 (da)
WO (1) WO1995002413A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US6811995B1 (en) * 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
AU739373B2 (en) * 1997-10-17 2001-10-11 Trustees Of The University Of Pennsylvania, The Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6750201B1 (en) 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6841153B1 (en) 1998-10-02 2005-01-11 University Of Florida Prevention of adhesions
CA2362565A1 (en) * 1999-02-22 2000-08-31 Eric F. Bernstein Compositions and methods for prevention of photoaging
US6986881B1 (en) * 1999-06-04 2006-01-17 Dana-Farber Cancer Institute, Inc. Identification of compounds that modify transcriptional responses to hypoxia
EP2360476B1 (en) * 2002-02-13 2017-10-25 BioMedica Diagnostics Inc. Methods for selecting treatment regimens and predicting outcomes in cancer patients
US20050244893A1 (en) * 2004-04-16 2005-11-03 Wyeth Novel method for determination of plasminogen activator inhibitor
CA2587854C (en) * 2004-11-18 2014-01-21 The Board Of Trustees Of The University Of Illinois Multicistronic sirna constructs to inhibit tumors
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
AU2006345660A1 (en) * 2006-06-01 2007-12-06 Japan As Represented By Director General Of Agency Of National Cancer Center Tumor suppressor
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US7771720B2 (en) * 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
US20220296999A1 (en) 2010-08-13 2022-09-22 Cfph, Llc Multi-process communication regarding gaming information
BR112016002753A2 (pt) * 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
EP3281016A1 (en) 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US4906457A (en) * 1988-09-06 1990-03-06 Washington State University Research Foundation, Inc. Compositions and methods for reducing the risk of sunlight and ultraviolet induced skin cancer
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US5744442A (en) * 1992-08-26 1998-04-28 Bristol Meyers Squibb Company Regulation of cellular invasiveness
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US5800814A (en) 1994-04-22 1998-09-01 Oklahoma Medical Research Foundation Method for inhibition of breast tumor growth
GB9410387D0 (en) 1994-05-24 1994-07-13 Xenova Ltd Pharmaceutical compounds
WO1997042973A1 (en) 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
JP4406206B2 (ja) * 2001-04-24 2010-01-27 バイエル コーポレーション ヒトｔｉｍｐ−１抗体
CA2561835A1 (en) * 2004-03-30 2005-10-13 Den Kgl. Veterinaer-Og Landbohojskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors

Also Published As

Publication number Publication date
US20010034327A1 (en) 2001-10-25
ES2217268T3 (es) 2004-11-01
JPH10500097A (ja) 1998-01-06
US20080166354A1 (en) 2008-07-10
ATE263569T1 (de) 2004-04-15
DE69433685D1 (de) 2004-05-13
EP0712312A1 (en) 1996-05-22
WO1995002413A1 (en) 1995-01-26
AU7183394A (en) 1995-02-13
DE69433685T2 (de) 2005-03-03
US6224865B1 (en) 2001-05-01
EP0712312B1 (en) 2004-04-07
US20030096755A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
ATE263569T1 (de) Unterdrückung von inhibitoren
GR3033103T3 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
Howes et al. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators
DE60036025D1 (de) Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
AU2483000A (en) Treatment of asthma with mek inhibitors
WO2004010937A3 (en) Method of treating cancer
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
DE60213386D1 (de) Geldanamycinderivate zur krebsbehandlung
NO962568L (no) Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
GB2405147A (en) Therapeutic molecules and methods-1
GB9321061D0 (en) Analgestic agent and its use
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
NO983992L (no) Serinprotease inhibitorer
NZ331484A (en) Serine protease inhibitors having an alkynylamino side chain for use in treatment of thrombin related diseases
TR199802638T2 (xx) Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
ATE277943T1 (de) Trypsininhibitoren
AU1565599A (en) A method for the prevention and treatment of stunned myocardium
CA2178528A1 (en) Therapeutics Containing 5alpha - Reductase Inhibitors

Legal Events

Date Code Title Description
A0 Application filed
AHS Application shelved for other reasons than non-payment